Vitamin K2 MK-7 (Menaquinone-7) 180 mcg by Carlson — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

2 Softgel(s) Serving Size

90 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K2

180 mcg

✅ 1.5× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.18mg

Other Ingredients

Safflower Oil Beef Gelatin Glycerin Water Carob Sunflower Oil Antioxidant Blend

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating) Gluten Free

Product Information

📋 Directions for Use

Directions: Adults: take two soft gels daily at mealtime.

⚠️ Warnings & Precautions

Warning: Vitamin K can antagonize the effect of anticoagulants, including Warfarin. Do not take this product if you are taking Warfarin or are pregnant or breastfeeding without first consulting with your physician.

🧪 Formulation Notes

Bone support Cardiovascular function Calcium Bioavailability

Gluten-free No artificial preservatives

An FDA regulated facility

Vitamin K2 as MK-7, derived from chickpeas, is important for the formation of strong, healthy bones and promotes arterial health.

Potency & quality guaranteed

Additional Information

Providing the highest quality nutritional supplements since 1965

Keep bottle tightly closed. Store away from heat and moisture.

Product Details

UPC / SKU 0 88395 10830 3

DSLD Entry Date 2022-05-19

Product Type Vitamin

Form Softgel Capsule

Brand Carlson

DSLD ID 266363

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation